Legal & General Group Plc Has $5.89 Million Position in Adaptive Biotechnologies Corporation $ADPT

Legal & General Group Plc lifted its stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 47.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 362,381 shares of the company’s stock after purchasing an additional 116,454 shares during the quarter. Legal & General Group Plc’s holdings in Adaptive Biotechnologies were worth $5,885,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of ADPT. EverSource Wealth Advisors LLC increased its holdings in shares of Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after purchasing an additional 1,565 shares in the last quarter. Assetmark Inc. increased its holdings in shares of Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after purchasing an additional 2,708 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of Adaptive Biotechnologies by 593.5% in the third quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company’s stock valued at $59,000 after purchasing an additional 3,371 shares in the last quarter. Caxton Associates LLP acquired a new stake in shares of Adaptive Biotechnologies in the first quarter valued at approximately $93,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Adaptive Biotechnologies by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,419 shares of the company’s stock valued at $120,000 after purchasing an additional 1,532 shares in the last quarter. Institutional investors and hedge funds own 99.17% of the company’s stock.

Analyst Upgrades and Downgrades

ADPT has been the subject of a number of research reports. BTIG Research reissued a “buy” rating and issued a $22.00 price target on shares of Adaptive Biotechnologies in a report on Wednesday, May 6th. Morgan Stanley lowered their target price on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. TD Cowen lifted their target price on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Monday, April 20th. Finally, Wall Street Zen lowered shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Adaptive Biotechnologies currently has an average rating of “Moderate Buy” and an average target price of $19.57.

Insider Buying and Selling

In other news, insider Harlan S. Robins sold 470,266 shares of the business’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total value of $6,193,403.22. Following the completion of the transaction, the insider owned 1,522,058 shares of the company’s stock, valued at $20,045,503.86. The trade was a 23.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Susan Bobulsky sold 41,338 shares of the business’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total transaction of $544,421.46. Following the completion of the transaction, the insider directly owned 427,775 shares of the company’s stock, valued at $5,633,796.75. This trade represents a 8.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 1,740,155 shares of company stock worth $23,468,600 over the last ninety days. Insiders own 5.70% of the company’s stock.

Adaptive Biotechnologies Stock Performance

ADPT opened at $16.90 on Monday. The company has a fifty day moving average price of $14.17 and a two-hundred day moving average price of $15.62. Adaptive Biotechnologies Corporation has a 52 week low of $9.90 and a 52 week high of $20.76. The firm has a market capitalization of $2.70 billion, a PE ratio of -51.21 and a beta of 2.15.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The firm had revenue of $70.87 million during the quarter, compared to analyst estimates of $61.03 million. During the same quarter in the previous year, the business earned ($0.20) EPS. The business’s quarterly revenue was up 35.1% compared to the same quarter last year. Equities analysts forecast that Adaptive Biotechnologies Corporation will post -0.48 EPS for the current year.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.